Fig. 5From: A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resectionForest plot of recurrence rate outcomes in patients who received sorafenib therapy for HCC after resection. HCC, hepatocellular carcinomaBack to article page